Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative COI-B for high-risk or borderline resectable colorectal liver metastases
2013-001362-42Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin, irinotecan and bevacizumab in colorectal cancer (CRC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: major pathologic response. Started May 2013; status: completed.
02
Drugs
capecitabineoxaliplatinirinotecanbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2013-001362-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001362-42.